Excess Soluble CD40L Contributes to Blood Brain Barrier Permeability In Vivo: Implications for HIV-Associated Neurocognitive Disorders

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Davidson, Donna C ^a   Hirschman, Michael P ^a   Sun, Anita ^a   Singh, Meera V ^a   Kasischke, Karl ^a,b   Maggirwar, Sanjay B ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD40 LIGAND; CHEMOKINE RECEPTOR CCR2; GRANULOCYTE ANTIBODY; THROMBOCYTE FACTOR 4; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; BLOOD CELL COUNT; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; HIV ASSOCIATED DEMENTIA; IN VIVO STUDY; LEUKOCYTE ADHERENCE; LYMPHOCYTIC INFILTRATION; MALE; MEMBRANE PERMEABILITY; MICROVASCULATURE; MONOCYTE; MOUSE; MULTIPHOTON MICROSCOPY; NONHUMAN; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE ACTIVATION;

AIDS DEMENTIA COMPLEX; ANIMALS; BLOOD PLATELETS; BLOOD-BRAIN BARRIER; BRAIN; CD40 LIGAND; ENDOTHELIAL CELLS; HIV INFECTIONS; HUMANS; INFLAMMATION MEDIATORS; MICE; MICE, INBRED C57BL; MONOCYTES; PERMEABILITY; PLATELET ACTIVATION; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

ANIMALIA; MUS;

EID: 84871224605     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051793     Document Type: Article

References (97)

1. van Kooten C, Banchereau J, (2000) CD40-CD40 ligand. J Leukoc Biol 67: 2-17.
2. Mazzei GJ, Edgerton MD, Losberger C, Lecoanet-Henchoz S, Graber P, et al. (1995) Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem 270: 7025-7028.
3. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR, (2002) Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106: 896-899.
4. Holme PA, Muller F, Solum NO, Brosstad F, Froland SS, et al. (1998) Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J 12: 79-89.
5. Mayne E, Funderburg NT, Sieg SF, Asaad R, Kalinowska M, et al. (2012) Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression. J Acquir Immune Defic Syndr 59: 340-346.
6. Ragin AB, D'Souza G, Reynolds S, Miller E, Sacktor N, et al. (2011) Platelet decline as a predictor of brain injury in HIV infection. J Neurovirol 17: 487-495.
7. Wachtman LM, Skolasky RL, Tarwater PM, Esposito D, Schifitto G, et al. (2007) Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus-associated dementia. Arch Neurol 64: 1264-1272.
8. Sui Z, Sniderhan LF, Schifitto G, Phipps RP, Gelbard HA, et al. (2007) Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia. J Immunol 178: 3226-3236.
9. Ramirez SH, Fan S, Dykstra H, Reichenbach N, Del Valle L, et al. (2010) Dyad of CD40/CD40 ligand fosters neuroinflammation at the blood-brain barrier and is regulated via JNK signaling: implications for HIV-1 encephalitis. J Neurosci 30: 9454-9464.
10. Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, et al. (2007) Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 6: 650-661.
11. Avison MJ, Nath A, Greene-Avison R, Schmitt FA, Bales RA, et al. (2004) Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. J Neurovirol 10: 223-232.
12. Kaul M, Garden GA, Lipton SA, (2001) Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410: 988-994.
13. Iadecola C, (2010) The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 120: 287-296.
14. Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, et al. (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75: 2087-2096.
15. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, et al. (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24: 1243-1250.
16. Gonzalez-Scarano F, Martin-Garcia J, (2005) The neuropathogenesis of AIDS. Nat Rev Immunol 5: 69-81.
17. Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L Jr, et al. (1999) Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282: 1627-1632.
18. Chun TW, Nickle DC, Justement JS, Meyers JH, Roby G, et al. (2008) Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 197: 714-720.
19. Chun TW, Nickle DC, Justement JS, Large D, Semerjian A, et al. (2005) HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 115: 3250-3255.
20. Rumbaugh JA, Steiner J, Sacktor N, Nath A, (2008) Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction. Futur HIV Ther 2: 271-280.
21. Kaul M, (2009) HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches. Curr Opin Neurol 22: 315-320.
22. Churchill MJ, Wesselingh SL, Cowley D, Pardo CA, McArthur JC, et al. (2009) Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol 66: 253-258.
23. Ma M, Nath A, (1997) Molecular determinants for cellular uptake of Tat protein of human immunodeficiency virus type 1 in brain cells. J Virol 71: 2495-2499.
24. Cui Z, Patel J, Tuzova M, Ray P, Phillips R, et al. (2004) Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles. Vaccine 22: 2631-2640.
25. Rumbaugh J, Turchan-Cholewo J, Galey D, St Hillaire C, Anderson C, et al. (2006) Interaction of HIV Tat and matrix metalloproteinase in HIV neuropathogenesis: a new host defense mechanism. FASEB J 20: 1736-1738.
26. Kim HJ, Martemyanov KA, Thayer SA, (2008) Human immunodeficiency virus protein Tat induces synapse loss via a reversible process that is distinct from cell death. J Neurosci 28: 12604-12613.
27. Perry SW, Barbieri J, Tong N, Polesskaya O, Pudasaini S, et al. (2010) Human immunodeficiency virus-1 Tat activates calpain proteases via the ryanodine receptor to enhance surface dopamine transporter levels and increase transporter-specific uptake and Vmax. J Neurosci 30: 14153-14164.
28. Davidson DC, Hirschman MP, Spinelli SL, Morrell CN, Schifitto G, et al. (2011) Antiplatelet activity of valproic acid contributes to decreased soluble CD40 ligand production in HIV type 1-infected individuals. J Immunol 186: 584-591.
29. Renshaw BR, Fanslow WC, 3rd, Armitage RJ, Campbell KA, Liggitt D, et al (1994) Humoral immune responses in CD40 ligand-deficient mice. J Exp Med 180: 1889-1900.
30. Lazarevic V, Myers AJ, Scanga CA, Flynn JL, (2003) CD40, but not CD40L, is required for the optimal priming of T cells and control of aerosol M. tuberculosis infection. Immunity 19: 823-835.
31. Piguet PF, Kan CD, Vesin C, Rochat A, Donati Y, et al. (2001) Role of CD40-CD40L in mouse severe malaria. Am J Pathol 159: 733-742.
32. Beland JL, Adler H, Del-Pan NC, Kozlow W, Sung J, et al. (1998) Recombinant CD40L treatment protects allogeneic murine bone marrow transplant recipients from death caused by herpes simplex virus-1 infection. Blood 92: 4472-4478.
33. Yacoub D, Hachem A, Theoret JF, Gillis MA, Mourad W, et al. (2010) Enhanced levels of soluble CD40 ligand exacerbate platelet aggregation and thrombus formation through a CD40-dependent tumor necrosis factor receptor-associated factor-2/Rac1/p38 mitogen-activated protein kinase signaling pathway. Arterioscler Thromb Vasc Biol 30: 2424-2433.
34. Bergmeier W, Rackebrandt K, Schroder W, Zirngibl H, Nieswandt B, (2000) Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies. Blood 95: 886-893.
35. Nieswandt B, Bergmeier W, Rackebrandt K, Gessner JE, Zirngibl H, (2000) Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood 96: 2520-2527.
36. Kasischke KA, Lambert EM, Panepento B, Sun A, Gelbard HA, et al. (2011) Two-photon NADH imaging exposes boundaries of oxygen diffusion in cortical vascular supply regions. J Cereb Blood Flow Metab 31: 68-81.
37. Polesskaya O, Silva J, Sanfilippo C, Desrosiers T, Sun A, et al. (2011) Methamphetamine causes sustained depression in cerebral blood flow. Brain Res 1373: 91-100.
38. Polesskaya O, Sun A, Salahura G, Silva JN, Dewhurst S, et al. (2012) Detection of Microregional Hypoxia in Mouse Cerebral Cortex by Two-photon Imaging of Endogenous NADH Fluorescence. J Vis Exp.
39. Li G, Liu Y, Tzeng NS, Cui G, Block ML, et al. (2005) Protective effect of dextromethorphan against endotoxic shock in mice. Biochem Pharmacol 69: 233-240.
40. Chen L, Swartz KR, Toborek M, (2009) Vessel microport technique for applications in cerebrovascular research. J Neurosci Res 87: 1718-1727.
41. Flaujac C, Boukour S, Cramer-Borde E, (2010) Platelets and viruses: an ambivalent relationship. Cell Mol Life Sci 67: 545-556.
42. Torre D, Pugliese A, (2008) Platelets and HIV-1 infection: old and new aspects. Curr HIV Res 6: 411-418.
43. Ishikawa M, Vowinkel T, Stokes KY, Arumugam TV, Yilmaz G, et al. (2005) CD40/CD40 ligand signaling in mouse cerebral microvasculature after focal ischemia/reperfusion. Circulation 111: 1690-1696.
44. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, et al. (2009) Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325: 612-616.
45. Beck WS (1991) Hematology. Cambridge, Mass.: MIT Press. xvi, 667 p.
46. Chamberlain KG, Tong M, Penington DG, (1990) Properties of the exchangeable splenic platelets released into the circulation during exercise-induced thrombocytosis. Am J Hematol 34: 161-168.
47. Graf D, Muller S, Korthauer U, van Kooten C, Weise C, et al. (1995) A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 25: 1749-1754.
48. Strauss-Ayali D, Conrad SM, Mosser DM, (2007) Monocyte subpopulations and their differentiation patterns during infection. J Leukoc Biol 82: 244-252.
49. Geissmann F, Jung S, Littman DR, (2003) Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19: 71-82.
50. Gordon S, Taylor PR, (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5: 953-964.
51. O'Dea KP, Dokpesi JO, Tatham KC, Wilson MR, Takata M, (2011) Regulation of monocyte subset proinflammatory responses within the lung microvasculature by the p38 MAPK/MK2 pathway. Am J Physiol Lung Cell Mol Physiol 301: L812-821.
52. Liu YY, Sun LC, Wei JJ, Li D, Yuan Y, et al. (2010) Tumor cell-released TLR4 ligands stimulate Gr-1+CD11b+F4/80+ cells to induce apoptosis of activated T cells. J Immunol 185: 2773-2782.
53. Varga G, Ehrchen J, Tsianakas A, Tenbrock K, Rattenholl A, et al. (2008) Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells. J Leukoc Biol 84: 644-650.
54. Zlokovic BV, (2011) Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12: 723-738.
55. Williams DW, Eugenin EA, Calderon TM, Berman JW, (2012) Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis. J Leukoc Biol 91: 401-415.
56. Wang J, Zhang W, Nardi MA, Li Z, (2011) HIV-1 Tat-induced platelet activation and release of CD154 contribute to HIV-1-associated autoimmune thrombocytopenia. J Thromb Haemost 9: 562-573.
57. Del Sorbo L, Arese M, Giraudo E, Tizzani M, Biancone L, et al. (2001) Tat-induced platelet-activating factor synthesis contributes to the angiogenic effect of HIV-1 Tat. Eur J Immunol 31: 376-383.
58. Del Sorbo L, DeMartino A, Biancone L, Bussolati B, Conaldi PG, et al. (1999) The synthesis of platelet-activating factor modulates chemotaxis of monocytes induced by HIV-1 Tat. Eur J Immunol 29: 1513-1521.
59. Otterdal K, Pedersen TM, Solum NO, (2004) Release of soluble CD40 ligand after platelet activation: studies on the solubilization phase. Thromb Res 114: 167-177.
60. Hermann A, Rauch BH, Braun M, Schror K, Weber AA, (2001) Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 12: 74-82.
61. Rizvi M, Pathak D, Freedman JE, Chakrabarti S, (2008) CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol Med 14: 530-538.
62. Giunta B, Rezai-Zadeh K, Tan J, (2010) Impact of the CD40-CD40L dyad in Alzheimer's disease. CNS Neurol Disord Drug Targets 9: 149-155.
63. Tan J, Town T, Paris D, Mori T, Suo Z, et al. (1999) Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 286: 2352-2355.
64. Tan J, Town T, Paris D, Placzek A, Parker T, et al. (1999) Activation of microglial cells by the CD40 pathway: relevance to multiple sclerosis. J Neuroimmunol 97: 77-85.
65. Tan J, Town T, Crawford F, Mori T, DelleDonne A, et al. (2002) Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci 5: 1288-1293.
66. D'Aversa TG, Weidenheim KM, Berman JW, (2002) CD40-CD40L interactions induce chemokine expression by human microglia: implications for human immunodeficiency virus encephalitis and multiple sclerosis. Am J Pathol 160: 559-567.
67. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, et al. (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391: 591-594.
68. Chakrabarti S, Blair P, Freedman JE, (2007) CD40-40L signaling in vascular inflammation. J Biol Chem 282: 18307-18317.
69. Chen C, Chai H, Wang X, Jiang J, Jamaluddin MS, et al. (2008) Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells. Blood 112: 3205-3216.
70. Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S, (2002) CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 106: 981-986.
71. Mondal S, Roy A, Pahan K, (2009) Functional blocking monoclonal antibodies against IL-12p40 homodimer inhibit adoptive transfer of experimental allergic encephalomyelitis. J Immunol 182: 5013-5023.
72. Hurst RD, Azam S, Hurst A, Clark JB, (2001) Nitric-oxide-induced inhibition of glyceraldehyde-3-phosphate dehydrogenase may mediate reduced endothelial cell monolayer integrity in an in vitro model blood-brain barrier. Brain Res 894: 181-188.
73. Schulze C, Smales C, Rubin LL, Staddon JM, (1997) Lysophosphatidic acid increases tight junction permeability in cultured brain endothelial cells. J Neurochem 68: 991-1000.
74. Staddon JM, Herrenknecht K, Smales C, Rubin LL, (1995) Evidence that tyrosine phosphorylation may increase tight junction permeability. J Cell Sci 108 (Pt 2): 609-619.
75. Deeks SG, (2011) HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 62: 141-155.
76. Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, et al. (2010) Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr 55: 316-322.
77. Appay V, Sauce D, (2008) Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 214: 231-241.
78. Huber JD, Egleton RD, Davis TP, (2001) Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci 24: 719-725.
79. Ballabh P, Braun A, Nedergaard M, (2004) The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 16: 1-13.
80. Gannon P, Khan MZ, Kolson DL, (2011) Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol 24: 275-283.
81. Nath A, Conant K, Chen P, Scott C, Major EO, (1999) Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J Biol Chem 274: 17098-17102.
82. Xiao H, Neuveut C, Tiffany HL, Benkirane M, Rich EA, et al. (2000) Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci U S A 97: 11466-11471.
83. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF, (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569-1572.
84. Li W, Huang Y, Reid R, Steiner J, Malpica-Llanos T, et al. (2008) NMDA receptor activation by HIV-Tat protein is clade dependent. J Neurosci 28: 12190-12198.
85. Kiebala M, Polesskaya O, Yao Z, Perry SW, Maggirwar SB, (2010) Nuclear factor-kappa B family member RelB inhibits human immunodeficiency virus-1 Tat-induced tumor necrosis factor-alpha production. PLoS One 5: e11875.
86. Lu SM, Tremblay ME, King IL, Qi J, Reynolds HM, et al. (2011) HIV-1 Tat-induced microgliosis and synaptic damage via interactions between peripheral and central myeloid cells. PLoS One 6: e23915.
87. Chen L, Choi JJ, Choi YJ, Hennig B, Toborek M (2012) HIV-1 Tat-induced cerebrovascular toxicity is enhanced in mice with amyloid deposits. Neurobiol Aging.
88. Fiala M, Looney DJ, Stins M, Way DD, Zhang L, et al. (1997) TNF-alpha opens a paracellular route for HIV-1 invasion across the blood-brain barrier. Mol Med 3: 553-564.
89. Toneatto S, Finco O, van der Putten H, Abrignani S, Annunziata P, (1999) Evidence of blood-brain barrier alteration and activation in HIV-1 gp120 transgenic mice. AIDS 13: 2343-2348.
90. Kanmogne GD, Schall K, Leibhart J, Knipe B, Gendelman HE, et al. (2007) HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis. J Cereb Blood Flow Metab 27: 123-134.
91. Kanmogne GD, Primeaux C, Grammas P, (2005) HIV-1 gp120 proteins alter tight junction protein expression and brain endothelial cell permeability: implications for the pathogenesis of HIV-associated dementia. J Neuropathol Exp Neurol 64: 498-505.
92. Singh MV, Davidson DC, Kiebala M, Maggirwar SB (2012) Detection of circulating platelet-monocyte complexes in persons infected with human immunodeficiency virus type-1. J Virol Methods.
93. Eugenin EA, Osiecki K, Lopez L, Goldstein H, Calderon TM, et al. (2006) CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS. J Neurosci 26: 1098-1106.
94. Law CL, Grewal IS, (2009) Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges. Adv Exp Med Biol 647: 8-36.
95. Daoussis D, Andonopoulos AP, Liossis SN, (2004) Targeting CD40L: a promising therapeutic approach. Clin Diagn Lab Immunol 11: 635-641.
96. Schifitto G, Peterson DR, Zhong J, Ni H, Cruttenden K, et al. (2006) Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology 66: 919-921.
97. Rieg G, Yeaman M, Lail AE, Donfield SM, Gomperts ED, et al. (2007) Platelet count is associated with plasma HIV type 1 RNA and disease progression. AIDS Res Hum Retroviruses 23: 1257-1261.